5 completed, 2 terminated, 1 active not recruiting, 1 no longer available. 7 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Terminated 2, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 3 | Terminated 2, Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow IMM-101: new trials by email Literature Review of IMM-101 trials Research Report on IMM-101
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer IMM-101, Pembrolizumab, Gemcitabine - Neoplasms Pancreatic | Phase 2 | Withdrawn | Karen Carty | 2024-06-17 | 2025-07-11 | |
| Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin Atezolizumab, IMM-101 - Colorectal Cancer | Phase 2 | Active not recruiting | AIO-Studien-gGmbH | 80 | 2021-12-10 | 2025-06-15 |
| Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure IMM-101, Observation - Cancer, Covid-19 | Phase 3 | Completed | Canadian Cancer Trials Group | 195 | 2020-10-01 | 2025-12-30 |
| A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma Nivolumab, Ipilimumab, IMM-101 - Melanoma | Phase 2 | Completed | Immodulon Therapeutics Ltd | 16 | 2018-10-04 | 2024-04-29 |
| Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer IMM-101, Gemcitabine, Nab-paclitaxel - Metastatic Cancer | Phase 1 / Phase 2 | Terminated | Immodulon Therapeutics Ltd | 2 | 2017-05-31 | 2024-11-25 |
| A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer Mycobacterium obuense, SBRT - Metastatic Colorectal Cancer | Phase 2 | Completed | Immodulon Therapeutics Ltd | 12 | 2012-05-30 | 2024-11-25 |
| A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001 IMM-101 - Malignant Melanoma | Phase 1 / Phase 2 | Terminated | Immodulon Therapeutics Ltd | 10 | 2012-02-01 | 2023-06-22 |
| A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer IMM-101, Gemcitabine - Advanced Pancreatic Cancer | Phase 2 | Completed | Immodulon Therapeutics Ltd | 110 | 2011-06-01 | 2021-11-10 |
| A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients Heat killed whole cell M. obuense (IMM-101) 0.1 mg, Heat-killed whole cell M.obuense (IMM-101) 0.5 mg, Heat killed whole cell M.obuense (IMM-101) 1.0 mg - Melanoma | Phase 1 | Completed | Immodulon Therapeutics Ltd | 19 | 2010-03-01 | 2012-12-06 |
| Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer IMM-101 - Pancreas Cancer, Pancreatic Cancer | No longer available | Impatients N.V. trading as myTomorrows | 2020-08-14 |
Melanoma (4) · Colorectal Neoplasms (2) · Pancreatic Neoplasms (2) · COVID-19 (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Sarcoma (1) · Turcot syndrome (1)
Immodulon Therapeutics Ltd (6) · AIO-Studien-gGmbH (1) · Canadian Cancer Trials Group (1) · Impatients N.V. trading as myTomorrows (1) · Karen Carty (1)
United Kingdom (8) · France (2) · Canada (1) · Cyprus (1) · Germany (1) · Ireland (1) · Italy (1) · Spain (1)
Alberto Fusi (1) · Alberto Fusi, Dr (1) · Andrew Gaya (1) · Angus Dalgleish, Professor (1) · David Chang (1) · David Cunningham, MD FRCP (1) · Jeff Evans (1) · Justin Stebbings, Professor (1) · Rebecca A Auer (1) · Stefan Kasper-Virchow, MD (1)
2009 (1), 2016 (1)